{"id":500476,"date":"2025-10-15T03:40:37","date_gmt":"2025-10-15T03:40:37","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/500476\/"},"modified":"2025-10-15T03:40:37","modified_gmt":"2025-10-15T03:40:37","slug":"genetic-testing-of-common-and-rare-variants-in-dementia-patients-from-a-memory-clinic-alzheimers-research-therapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/500476\/","title":{"rendered":"Genetic testing of common and rare variants in dementia patients from a memory clinic | Alzheimer’s Research & Therapy"},"content":{"rendered":"
  • \n

    2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 19, 1598\u20131695 (2023).<\/p>\n<\/li>\n

  • \n

    Campion D, et al. Early-onset autosomal dominant alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664\u201370.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Sherrington R, et al. Cloning of a gene bearing missense mutations in early-onset Familial alzheimer\u2019s disease. Nature. 1995;375:754\u201360.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rogaev EI, et al. Familial alzheimer\u2019s disease in kindreds with missense mutations in a gene on chromosome 1 related to the alzheimer\u2019s disease type 3 gene. Nature. 1995;376:775\u20138.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12:383\u20138.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lanoisel\u00e9e HM et al. APP, PSEN1, and PSEN2 mutations in early-onset alzheimer disease: A genetic screening study of Familial and sporadic cases. PLoS Med 14, (2017).<\/p>\n<\/li>\n

  • \n

    Goldman JS, et al. Genetic counseling and testing for alzheimer disease: joint practice guidelines of the American college of medical genetics and the National society of genetic counselors. Genet Sci. 2011;13:597.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Pilotto A, Padovani A, Borroni B, Clinical. Biological, and Imaging Features of Monogenic Alzheimer\u2019s Disease. Biomed Res Int 2013, (2013).<\/p>\n<\/li>\n

  • \n

    Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genetics in Medicine 2018 20:10 20, 1122\u20131130 (2018).<\/p>\n<\/li>\n

  • \n

    Carmona S, Hardy J, Guerreiro R. The genetic landscape of alzheimer disease. Handb Clin Neurol. 2018;148:395\u2013408.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bellenguez C, et al. New insights into the genetic etiology of alzheimer\u2019s disease and related dementias. Nat Genet. 2022;2022:1\u201325. https:\/\/doi.org\/10.1038\/s41588-022-01024-z<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    de Rojas I, et al. Common variants in alzheimer\u2019s disease and risk stratification by polygenic risk scores. Nat Commun. 2021;12:3417.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wightman DP, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for alzheimer\u2019s disease. Nat Genet. 2021;53:1276\u201382.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Escott-Price V, et al. Polygenic score prediction captures nearly all common genetic risk for alzheimer\u2019s disease. Neurobiol Aging. 2016;0:3\u20131342.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chaudhury S et al. Alzheimer\u2019s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. Translational Psychiatry 2019 9:1 9, 1\u20137 (2019).<\/p>\n<\/li>\n

  • \n

    Martiskainen H, et al. Effects of alzheimer\u2019s disease-Associated risk loci on cerebrospinal fluid biomarkers and disease progression: A polygenic risk score approach. J Alzheimer\u2019s Disease. 2015;43:565\u201373.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12:1\u201311.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    L\u00e4ll K, M\u00e4gi R, Morris A, Metspalu A, Fischer K. Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores. Genet Med. 2017;19:322\u20139.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tesi N, et al. Polygenic risk score of longevity predicts longer survival across an age continuum. Journals Gerontology: Ser A. 2021;76:750\u20139.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fahed AC, Philippakis AA, Khera AV. The potential of polygenic scores to improve cost and efficiency of clinical trials. Nature Communications 2022 13:1 13, 1\u20134 (2022).<\/p>\n<\/li>\n

  • \n

    Guerreiro R, et al. TREM2 variants in alzheimer\u2019s disease. N Engl J Med. 2013;368:117\u201327.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jonsson T, et al. Variant of TREM2 associated with the risk of alzheimer\u2019s disease. N Engl J Med. 2013;368:107\u201316.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Sims R et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in alzheimer\u2019s disease. Nat Genet 49, (2017).<\/p>\n<\/li>\n

  • \n

    Holstege H, et al. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for alzheimer\u2019s disease. Nat Genet. 2022;2022:1\u20139. https:\/\/doi.org\/10.1038\/s41588-022-01208-7<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jin SC, et al. Coding variants in TREM2 increase risk for alzheimer\u2019s disease. Hum Mol Genet. 2014;23:5838\u201346.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jay TR, Saucken V, V. E., Landreth GE. TREM2 in Neurodegenerative Diseases. Molecular Neurodegeneration 2017 12:1 12, 1\u201333 (2017).<\/p>\n<\/li>\n

  • \n

    Corder E, Saunders A. Gene dose of Apolipoprotein E type 4 allele and the risk of alzheimer\u2019s disease in late onset families. Sci (1979). 1993;8:41\u20133.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Corder EH, et al. Protective effect of Apolipoprotein E type 2 allele for late onset alzheimer disease. Nat Genet. 1994;7:180\u20134.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rubin R. Studying how genomic variation affects human health. JAMA 326, (2021).<\/p>\n<\/li>\n

  • \n

    Chia R, et al. Genome sequencing analysis identifies new loci associated with lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021;53:294\u2013303.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Perrone F, Cacace R, van der Zee J, Van Broeckhoven C. Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases. Genome Medicine 2021 13:1 13, 1\u201313 (2021).<\/p>\n<\/li>\n

  • \n

    Van Lee D. S. J. Prevalence of pathogenic variants and eligibility criteria for genetic testing in patients who visit a memory clinic. Neurology 104, (2025).<\/p>\n<\/li>\n

  • \n

    Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimer\u2019s Disease. 2018;62:1091\u2013111. (J Alzheimers Dis.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Van Der Flier WM et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. 41, 313\u2013327 (2014).<\/p>\n<\/li>\n

  • \n

    McKhann G, et al. Clinical diagnosis of alzheimer\u2019s disease: report of the NINCDS-ADRDA work group\u22c6 under the auspices of department of health and human services task force on alzheimer\u2019s disease. Neurology. 1984;34:939\u201344.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Dubois B, et al. Research criteria for the diagnosis of alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734\u201346.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester groups. J Neurol Neurosurg Psychiatry. 1994;57:416.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Journal of Alzheimer\u2019s Disease 9, 417\u2013423 (2006).<\/p>\n<\/li>\n

  • \n

    McKeith IG, et al. Diagnosis and management of dementia with lewy bodies. Neurology. 2017;89:88\u2013100.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Petersen RC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303\u20138.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    McKhann GM, et al. The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:263\u20139.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jack CR, et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:535\u201362.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Das S, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48:1284\u20137.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fuchsberger C, Abecasis GR, Hinds D. A. minimac2: faster genotype imputation. Bioinformatics. 2015;31:782\u20134.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Taliun D et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 2021 590:7845 590, 290\u2013299 (2021).<\/p>\n<\/li>\n

  • \n

    Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17:405\u201324.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Holm SA, Simple Sequentially. Rejective multiple test procedure. Scand J Stat. 1979. https:\/\/doi.org\/10.2307\/4615733<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Liu X, Li C, Mou C, Dong Y, Tu Y. DbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 2020;12:1\u20138.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Karczewski KJ et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020 581:7809 581, 434\u2013443 (2020).<\/p>\n<\/li>\n

  • \n

    Schramm C et al. Penetrance Estimation of alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes. Genome Med 14, (2022).<\/p>\n<\/li>\n

  • \n

    Corder EH, et al. Gene dose of Apolipoprotein E type 4 allele and the risk of alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Duncan L et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nature Communications 2019 10:1 10, 1\u20139 (2019).<\/p>\n<\/li>\n

  • \n

    Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 2007;17:1520\u20138.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748\u201352.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kim DH, et al. Genetic markers for diagnosis and pathogenesis of alzheimer\u2019s disease. Gene. 2014;545:185\u201393.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Escott-Price V, Schmidt KM. Probability of alzheimer\u2019s disease based on common and rare genetic variants. Alzheimers Res Ther. 2021;13:1\u20139.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Guerreiro R, et al. Investigating the genetic architecture of dementia with lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 2018;17:64\u201374.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rongve A et al. GBA and APOE \u03b54 associate with sporadic dementia with lewy bodies in European genome wide association study. Sci Rep 9, (2019).<\/p>\n<\/li>\n

  • \n

    Pottier C, et al. Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol. 2019;137:879\u201399.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Pottier C, et al. Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal dementia and GRN mutations: a genome-wide association study. Lancet Neurol. 2018;17:548.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Katsumata Y, et al. Multiple gene variants linked to Alzheimer\u2019s-type clinical dementia via GWAS are also associated with non-Alzheimer\u2019s neuropathologic entities. Neurobiol Dis. 2022;174:105880.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Dugan AJ, et al. Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study. Acta Neuropathol Commun. 2021;9:1\u201318.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Robinson JL, et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain. 2023;146:2557\u201369.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Nicolas G et al. Assessment of Mendelian and risk-factor genes in alzheimer disease: A prospective nationwide clinical utility study and recommendations for genetic screening. Genet Sci 26, (2024).<\/p>\n<\/li>\n

  • \n

    Jensen AMG et al. The SORL1 p.Y1816C variant causes impaired endosomal dimerization and autosomal dominant alzheimer\u2019s disease. Proc Natl Acad Sci U S A 121, (2024).<\/p>\n<\/li>\n

  • \n

    Fazeli E, Fazeli E, Fojt\u00edk P, Holstege H, Andersen OM. Functional characterization of SORL1 variants in cell-based assays to investigate variant pathogenicity. Philosophical Trans Royal Soc B: Biol Sci 379, (2024).<\/p>\n<\/li>\n

  • \n

    Hung C et al. SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network. Cell Rep 35, (2021).<\/p>\n<\/li>\n

  • \n

    Fazeli E et al. A Familial missense variant in the alzheimer\u2019s disease gene SORL1 impairs its maturation and endosomal sorting. Acta Neuropathol 147, (2024).<\/p>\n<\/li>\n

  • \n

    Nicolas A et al. Transferability of a European-derived Alzheimer\u2019s Disease Genetic Risk Score across Multi-Ancestry Populations. medRxiv (2023).<\/p>\n<\/li>\n

  • \n

    Escott-Price V, et al. Common polygenic variation enhances risk prediction for alzheimer\u2019s disease. Brain. 2015;138:3673\u201384.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Van Lee D. Genetics contributes to concomitant pathology and clinical presentation in dementia with lewy bodies. J Alzheimers Dis. 2021;83:269\u201379.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Sleegers K, et al. A 22-single nucleotide polymorphism alzheimer\u2019s disease risk score correlates with family history, onset age, and cerebrospinal fluid A\u03b2 42. Alzheimer\u2019s Dement. 2015;11:1452\u201360.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chouraki V, et al. Evaluation of a genetic risk score to improve risk prediction for alzheimer\u2019s disease. J Alzheimer\u2019s Disease. 2016;53:921\u201332.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rodr\u00edguez-Rodr\u00edguez E, et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to alzheimer\u2019s disease. J Neural Transm. 2013;120:807\u201312.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Klunk WE. Amyloid imaging as a biomarker for cerebral \u03b2-amyloidosis and risk-prediction for alzheimer dementia. Neurobiol Aging. 2011;32:S20.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Edison P, et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. NeuroImage. 2013;70:423\u201333.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tomassen J et al. Abnormal cerebrospinal fluid levels of amyloid and Tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study. Alzheimers Dement (N Y) 8, (2022).<\/p>\n<\/li>\n

  • \n

    Palmqvist S, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early alzheimer disease. Neurology. 2015;85:1240.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Shaffer JL, et al. Predicting cognitive decline in subjects at risk for alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology. 2013;266:583\u201391.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Walsh T, et al. Outreach, screening, and randomization of APOE \u03b54 carriers into an alzheimer\u2019s prevention trial: A global perspective from the API generation program. J Prev Alzheimers Dis. 2023;10:453.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    ALZ-801 for Early Alzheimer\u2019s in People With the APOE4\/4 Genotype. (APOLLOE4). https:\/\/www.alzheimers.gov\/clinical-trials\/alz-801-early-alzheimers-people-apoe4-4-genotype-apolloe4<\/a><\/p>\n<\/li>\n

  • \n

    Jackson S et al. INVOKE-2 – A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer\u2019s Disease (P17-3.005). Neurology 98, (2022).<\/p>\n<\/li>\n

  • \n

    Study Details |. First in Human Study for Safety and Tolerability of AL003. | ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT03822208?cond=Alzheimer<\/a> Disease&term\u2009=\u2009AL003&rank\u2009=\u20091.<\/p>\n<\/li>\n","protected":false},"excerpt":{"rendered":"2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 19, 1598\u20131695 (2023). Campion D, et al. Early-onset autosomal dominant…\n","protected":false},"author":2,"featured_media":500477,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[231,164273,164274,8747,267,164276,164275,233,19315,70,16,15],"class_list":{"0":"post-500476","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-alzheimers-disease","9":"tag-apoe","10":"tag-genetic-risk-score","11":"tag-genetic-testing","12":"tag-genetics","13":"tag-geriatric-psychiatry","14":"tag-geriatrics-gerontology","15":"tag-neurology","16":"tag-neurosciences","17":"tag-science","18":"tag-uk","19":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115376109851010785","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/500476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=500476"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/500476\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/500477"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=500476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=500476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=500476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}